Product logins

Find logins to all Clarivate products below.


Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)

The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical treatments are insufficient. The launch of newer, more-effective biologics (e.g., Eli Lilly’s IL-17 inhibitor Taltz, AbbVie’s latest-in-class IL-23 inhibitor Skyrizi, UCB’s IL-17 A/F dual inhibitor Bimzelx) has eroded the market share of long-established biologics such as AbbVie’s TNF-alpha inhibitor Humira, Johnson & Johnson Innovative Medicine’s IL-12/23 inhibitor Stelara, and Novartis’s IL-17 inhibitor Cosentyx. The emergence of multiple biosimilars of adalimumab is also increasing the competition in this market. Amgen’s PDE-4 inhibitor Otezla, the only oral targeted therapy for many years, is firmly enduring the competition from Sotyktu, an oral TYK2 inhibitor that showed clinical superiority to Otezla in two head-to-head trials.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
  • How have newer targeted agents such as Bimzelx and Sotyktu been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult psoriasis patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of adult psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Markets covered: United States

Key companies: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, UCB

Key drugs: Humira, Taltz, Bimzelx, Tremfya, Skyrizi, Otezla, Sotyktu, Vtama, Zoryve

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Related Market Assessment Reports

Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…